Tag Archives: JP Morgan

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

New Decade, New Agenda for Pharma

A new track for nonprofits, product diversification and the rise of the emerging markets —  Audrey S. Erbes reports on some of the takeaways from this week’s JP Morgan Healthcare Conference. There were some surprising changes in the format of the 29th Annual JP Morgan Healthcare Conference, the world’s premier health care industry investment meeting […]
Posted in Emerging Markets, Guest Blog, R&D | Also tagged , , , , | Leave a comment

JP Morgan Healthcare Conference:
It’s All About "Money…Rather the Economy!"

JP Morgan’s Healthcare Conference has always been about financing, but money has never been the main focus like it is at this year’s annual gathering in San Francisco. The hallmark of this investment meeting has been innovation, with companies passionately pitching their new product or technology and management team’s capability to execute on a business […]
Posted in Events | Also tagged , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta